open access

Vol 68, No 1 (2017)
REVIEWS — Postgraduate Education
Published online: 2016-12-02
Submitted: 2016-05-25
Accepted: 2016-07-11
Get Citation

Anti-Müllerian hormone and polycystic ovary syndrome

Agnieszka Łebkowska, Irina Kowalska
DOI: 10.5603/EP.a2016.0065
·
Pubmed: 27918066
·
Endokrynologia Polska 2017;68(1):74-78.

open access

Vol 68, No 1 (2017)
REVIEWS — Postgraduate Education
Published online: 2016-12-02
Submitted: 2016-05-25
Accepted: 2016-07-11

Abstract

Anti-Müllerian hormone (AMH) is a glycoprotein, a member of the transforming growth factor β family, reflecting the number of ovarian antral follicles. Polycystic ovary syndrome (PCOS) is a common endocrinopathy predisposing to infertility, and metabolic and cardiovascular complications. In our review, we discuss the role of AMH in PCOS pathophysiology and its clinical applications according to the published studies. Improvement of AMH assay validity will allow the clinical utility of this valuable biomarker to be widened. (Endokrynol Pol 2017; 68 (1): 74–78)

Abstract

Anti-Müllerian hormone (AMH) is a glycoprotein, a member of the transforming growth factor β family, reflecting the number of ovarian antral follicles. Polycystic ovary syndrome (PCOS) is a common endocrinopathy predisposing to infertility, and metabolic and cardiovascular complications. In our review, we discuss the role of AMH in PCOS pathophysiology and its clinical applications according to the published studies. Improvement of AMH assay validity will allow the clinical utility of this valuable biomarker to be widened. (Endokrynol Pol 2017; 68 (1): 74–78)

Get Citation

Keywords

AMH; PCOS; polycystic ovarian morphology; insulin resistance; assisted reproductive technology

About this article
Title

Anti-Müllerian hormone and polycystic ovary syndrome

Journal

Endokrynologia Polska

Issue

Vol 68, No 1 (2017)

Pages

74-78

Published online

2016-12-02

DOI

10.5603/EP.a2016.0065

Pubmed

27918066

Bibliographic record

Endokrynologia Polska 2017;68(1):74-78.

Keywords

AMH
PCOS
polycystic ovarian morphology
insulin resistance
assisted reproductive technology

Authors

Agnieszka Łebkowska
Irina Kowalska

References (60)
  1. Fauser BC, Tarlatzis BC, Rebar RW, et al. Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril. 2012; 97(1): 28–38.e25.
  2. Pigny P, Merlen E, Robert Y, et al. Elevated serum level of anti-mullerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest. J Clin Endocrinol Metab. 2003; 88(12): 5957–5962.
  3. Pigny P, Jonard S, Robert Y, et al. Serum anti-Mullerian hormone as a surrogate for antral follicle count for definition of the polycystic ovary syndrome. J Clin Endocrinol Metab. 2006; 91(3): 941–945.
  4. Dewailly D, Gronier H, Poncelet E, et al. Diagnosis of polycystic ovary syndrome (PCOS): revisiting the threshold values of follicle count on ultrasound and of the serum AMH level for the definition of polycystic ovaries. Hum Reprod. 2011; 26(11): 3123–3129.
  5. Piouka A, Farmakiotis D, Katsikis I, et al. Anti-Mullerian hormone levels reflect severity of PCOS but are negatively influenced by obesity: relationship with increased luteinizing hormone levels. Am J Physiol Endocrinol Metab. 2009; 296(2): E238–E243.
  6. Rey RA, Grinspon RP, Gottlieb S, et al. Male hypogonadism: an extended classification based on a developmental, endocrine physiology-based approach. Andrology. 2013; 1(1): 3–16.
  7. La Marca A, Volpe A. Anti-Müllerian hormone (AMH) in female reproduction: is measurement of circulating AMH a useful tool? Clin Endocrinol (Oxf). 2006; 64(6): 603–610.
  8. Dewailly D, Andersen CY, Balen A, et al. The physiology and clinical utility of anti-Mullerian hormone in women. Hum Reprod Update. 2014; 20(3): 370–385.
  9. Pellatt L, Rice S, Dilaver N, et al. Anti-Müllerian hormone reduces follicle sensitivity to follicle-stimulating hormone in human granulosa cells. Fertil Steril. 2011; 96(5): 1246–12451.e1.
  10. Andersen CY, Schmidt KT, Kristensen SG, et al. Concentrations of AMH and inhibin-B in relation to follicular diameter in normal human small antral follicles. Hum Reprod. 2010; 25(5): 1282–1287.
  11. Peluso C, Fonseca FLA, Rodart IF, et al. AMH: An ovarian reserve biomarker in assisted reproduction. Clin Chim Acta. 2014; 437: 175–182.
  12. Grynberg M, Pierre A, Rey R, et al. Differential regulation of ovarian anti-müllerian hormone (AMH) by estradiol through α- and β-estrogen receptors. J Clin Endocrinol Metab. 2012; 97(9): E1649–E1657.
  13. Gnoth C, Roos J, Broomhead D, et al. Antimüllerian hormone levels and numbers and sizes of antral follicles in regularly menstruating women of reproductive age referenced to true ovulation day. Fertil Steril. 2015; 104(6): 1535–15343.e1.
  14. Nielsen ME, Rasmussen IA, Kristensen SG, et al. In human granulosa cells from small antral follicles, androgen receptor mRNA and androgen levels in follicular fluid correlate with FSH receptor mRNA. Mol Hum Reprod. 2011; 17(1): 63–70.
  15. Andersen CY, Byskov AG. Estradiol and regulation of anti-Müllerian hormone, inhibin-A, and inhibin-B secretion: analysis of small antral and preovulatory human follicles' fluid. J Clin Endocrinol Metab. 2006; 91(10): 4064–4069.
  16. Visser JA, Durlinger ALL, Peters IJJ, et al. Increased oocyte degeneration and follicular atresia during the estrous cycle in anti-Müllerian hormone null mice. Endocrinology. 2007; 148(5): 2301–2308.
  17. Kelsey TW, Wright P, Nelson SM, et al. A validated model of serum anti-müllerian hormone from conception to menopause. PLoS One. 2011; 6(7): e22024.
  18. La Marca A, Spada E, Sighinolfi G, et al. Age-specific nomogram for the decline in antral follicle count throughout the reproductive period. Fertil Steril. 2011; 95(2): 684–688.
  19. Fanchin R, Schonäuer LM, Righini C, et al. Serum anti-Müllerian hormone is more strongly related to ovarian follicular status than serum inhibin B, estradiol, FSH and LH on day 3. Hum Reprod. 2003; 18(2): 323–327.
  20. Broekmans FJM, de Ziegler D, Howles CM, et al. The antral follicle count: practical recommendations for better standardization. Fertil Steril. 2010; 94(3): 1044–1051.
  21. Jeppesen JV, Anderson RA, Kelsey TW, et al. Which follicles make the most anti-Mullerian hormone in humans? Evidence for an abrupt decline in AMH production at the time of follicle selection. Mol Hum Reprod. 2013; 19(8): 519–527.
  22. Seifer DB, Golub ET, Lambert-Messerlian G, et al. Variations in serum müllerian inhibiting substance between white, black, and Hispanic women. Fertil Steril. 2009; 92(5): 1674–1678.
  23. Schuh-Huerta SM, Johnson NA, Rosen MP, et al. Genetic variants and environmental factors associated with hormonal markers of ovarian reserve in Caucasian and African American women. Hum Reprod. 2012; 27(2): 594–608.
  24. Lambert-Messerlian G, Plante B, Eklund EE, et al. Levels of antimüllerian hormone in serum during the normal menstrual cycle. Fertil Steril. 2016; 105(1): 208–213.e1.
  25. Bentzen JG, Forman JL, Pinborg A, et al. Ovarian reserve parameters: a comparison between users and non-users of hormonal contraception. Reprod Biomed Online. 2012; 25(6): 612–619.
  26. Nelson SM, Stewart F, Fleming R, et al. Longitudinal assessment of antimüllerian hormone during pregnancy-relationship with maternal adiposity, insulin, and adiponectin. Fertil Steril. 2010; 93(4): 1356–1358.
  27. Broer SL, van Disseldorp J, Broeze KA, et al. IMPORT study group. Added value of ovarian reserve testing on patient characteristics in the prediction of ovarian response and ongoing pregnancy: an individual patient data approach. Hum Reprod Update. 2013; 19(1): 26–36.
  28. Partridge AH, Ruddy KJ, Gelber S, et al. Ovarian reserve in women who remain premenopausal after chemotherapy for early stage breast cancer. Fertil Steril. 2010; 94(2): 638–644.
  29. Tehrani FR, Solaymani-Dodaran M, Azizi F. A single test of antimullerian hormone in late reproductive-aged women is a good predictor of menopause. Menopause. 2009; 16(4): 797–802.
  30. Broer SL, Eijkemans MJC, Scheffer GJ, et al. Anti-mullerian hormone predicts menopause: a long-term follow-up study in normoovulatory women. J Clin Endocrinol Metab. 2011; 96(8): 2532–2539.
  31. Dorman JS, Steenkiste AR, Foley TP, et al. Familial Autoimmune and Diabetes (FAD) Study. Menopause in type 1 diabetic women: is it premature? Diabetes. 2001; 50(8): 1857–1862.
  32. Soto N, Iñiguez G, López P, et al. Anti-Mullerian hormone and inhibin B levels as markers of premature ovarian aging and transition to menopause in type 1 diabetes mellitus. Hum Reprod. 2009; 24(11): 2838–2844.
  33. Voorhuis M, Onland-Moret NC, van der Schouw YT, et al. Human studies on genetics of the age at natural menopause: a systematic review. Hum Reprod Update. 2010; 16(4): 364–377.
  34. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group, Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004; 19(1): 41–47.
  35. McAllister JM, Legro RS, Modi BP, et al. Functional genomics of PCOS: from GWAS to molecular mechanisms. Trends Endocrinol Metab. 2015; 26(3): 118–124.
  36. Foltyn W, Strzelczyk J, Marek B, et al. Selected markers of endothelial dysfunction in women with polycystic ovary syndrome. Endokrynol Pol. 2011; 62(3): 243–248.
  37. Park AS, Lawson MA, Chuan SS, et al. Serum anti-mullerian hormone concentrations are elevated in oligomenorrheic girls without evidence of hyperandrogenism. J Clin Endocrinol Metab. 2010; 95(4): 1786–1792.
  38. Pellatt L, Hanna L, Brincat M, et al. Granulosa cell production of anti-Müllerian hormone is increased in polycystic ovaries. J Clin Endocrinol Metab. 2007; 92(1): 240–245.
  39. Das M, Gillott DJ, Saridogan E, et al. Anti-Mullerian hormone is increased in follicular fluid from unstimulated ovaries in women with polycystic ovary syndrome. Hum Reprod. 2008; 23(9): 2122–2126.
  40. Gilling-Smith C, Willis DS, Beard RW, et al. Hypersecretion of androstenedione by isolated thecal cells from polycystic ovaries. J Clin Endocrinol Metab. 1994; 79(4): 1158–1165.
  41. Diamanti-Kandarakis E, Christakou CD, Kandaraki E, et al. Polycystic ovarian syndrome: pathophysiology, molecular aspects and clinical implications. Expert Rev Mol Med. 2008; 10(2): e3–212.
  42. Cassar S, Teede HJ, Moran LJ, et al. Polycystic ovary syndrome and anti-Müllerian hormone: role of insulin resistance, androgens, obesity and gonadotrophins. Clin Endocrinol (Oxf). 2014; 81(6): 899–906.
  43. Pierre A, Peigné M, Grynberg M, et al. Loss of LH-induced down-regulation of anti-Müllerian hormone receptor expression may contribute to anovulation in women with polycystic ovary syndrome. Hum Reprod. 2013; 28(3): 762–769.
  44. Sahmay S, Atakul N, Oncul M, et al. Serum anti-Mullerian hormone levels in the main phenotypes of polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol. 2013; 170(1): 157–161.
  45. Tal R, Seifer DB, Khanimov M, et al. Characterization of women with elevated antimüllerian hormone levels (AMH): correlation of AMH with polycystic ovarian syndrome phenotypes and assisted reproductive technology outcomes. Am J Obstet Gynecol. 2014; 211(1): 59.e1–59.e8.
  46. Alebić MŠ, Stojanović N, Duhamel A, et al. The phenotypic diversity in per-follicle anti-Müllerian hormone production in polycystic ovary syndrome. Hum Reprod. 2015; 30(8): 1927–1933.
  47. Olszanecka-Glinianowicz M, Madej P, Owczarek A, et al. Circulating anti-Müllerian hormone levels in relation to nutritional status and selected adipokines levels in polycystic ovary syndrome. Clin Endocrinol (Oxf). 2015; 83(1): 98–104.
  48. Chen MJ, Yang WS, Chen CL, et al. The relationship between anti-Mullerian hormone, androgen and insulin resistance on the number of antral follicles in women with polycystic ovary syndrome. Hum Reprod. 2008; 23(4): 952–957.
  49. Grossman MP, Nakajima ST, Fallat ME, et al. Müllerian-inhibiting substance inhibits cytochrome P450 aromatase activity in human granulosa lutein cell culture. Fertil Steril. 2008; 89(5 Suppl): 1364–1370.
  50. Skałba P, Cygal A, Madej P, et al. Is the plasma anti-Müllerian hormone (AMH) level associated with body weight and metabolic, and hormonal disturbances in women with and without polycystic ovary syndrome? Eur J Obstet Gynecol Reprod Biol. 2011; 158(2): 254–259.
  51. Lujan ME, Jarrett BY, Brooks ED, et al. Updated ultrasound criteria for polycystic ovary syndrome: reliable thresholds for elevated follicle population and ovarian volume. Hum Reprod. 2013; 28(5): 1361–1368.
  52. Lauritsen MP, Bentzen JG, Pinborg A, et al. The prevalence of polycystic ovary syndrome in a normal population according to the Rotterdam criteria versus revised criteria including anti-Mullerian hormone. Hum Reprod. 2014; 29(4): 791–801.
  53. Sahmay S, Aydin Y, Oncul M, et al. Diagnosis of Polycystic Ovary Syndrome: AMH in combination with clinical symptoms. J Assist Reprod Genet. 2014; 31(2): 213–220.
  54. Dewailly D, Lujan ME, Carmina E, et al. Definition and significance of polycystic ovarian morphology: a task force report from the Androgen Excess and Polycystic Ovary Syndrome Society. Hum Reprod Update. 2014; 20(3): 334–352.
  55. Craciunas L, Roberts SA, Yates AP, et al. Modification of the Beckman-Coulter second-generation enzyme-linked immunosorbent assay protocol improves the reliability of serum antimüllerian hormone measurement. Fertil Steril. 2015; 103(2): 554–59.e1.
  56. Nelson SM, Pastuszek E, Kloss G, et al. Two new automated, compared with two enzyme-linked immunosorbent, antimüllerian hormone assays. Fertil Steril. 2015; 104(4): 1016–1021.e6.
  57. Burks HR, Ross L, Opper N, et al. Can highly sensitive antimüllerian hormone testing predict failed response to ovarian stimulation? Fertil Steril. 2015; 104(3): 643–648.
  58. Broekmans FJ, Kwee J, Hendriks DJ, et al. A systematic review of tests predicting ovarian reserve and IVF outcome. Hum Reprod Update. 2006; 12(6): 685–718.
  59. Seifer DB, MacLaughlin DT, Christian BP, et al. Early follicular serum müllerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles. Fertil Steril. 2002; 77(3): 468–471.
  60. Broer SL, Dólleman M, van Disseldorp J et al. Prediction of an excessive response in in vitro fertilization from patient characteristics and ovarian reserve tests and comparison in subgroups: an individual patient data meta-analysis. Fertil Steril 2013; 100: 420–429.e7. doi: 10.1016/j.fertnstert.2013.04.024

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl